Nicholas Vardy
Booking 101.64% Gains in Jazz Pharmaceuticals
Jazz Pharmaceuticals (JAZZ) jumped 4.89% over the past two days after announcing better-than-expected earnings. Quarterly revenues increased 67.7% year over year to $208.3 million. Second-quarter 2013 adjusted earnings of $1 per share were well above the year-ago earnings of 81 cents per share. With your September 2013 $70.000 calls (JAZZ130921C00070000) now up 101.64%, sell all […]
A Triple Play of ‘Buffett-Beating’ Investment Strategies
Warren Buffett is a hard man to outperform on the investment front. Yet, that’s exactly the goal I set for myself.
Booking 57.54% Gains in Jazz Pharmaceuticals
Jazz Pharmaceuticals (JAZZ) jumped 2.56% yesterday. Jazz, whose drugs include treatments for pain and narcolepsy, reports Q2 results after today’s close. Analysts forecast a 39% increase in earnings to $1.52 a share. Sales for the period are expected to jump 68% to $208.7 million. With your September 2013 $70 call options (JAZZ130921C00070000) now up 57.54%, […]
Betting on a Bounce in Gentherm (THRM)
It was another solid week for global stock markets last week, with the Dow Jones up 0.64% and S&P 500 rising 1.07%. The MCSI Emerging Markets Index took a breather and was down 0.30%. Big gainers in your Bull Market Alert portfolio included Jazz Pharmaceuticals (JAZZ), jumping 2.40%; Celgene Corporation (CELG), up 2.37%; Bank of […]
Steady As She Goes…
It was the first negative week in a month or so, with the S&P 500 down 0.38% and the MCSI Emerging Markets Index tumbling 2.14%. Big gainers in your Alpha Investor Letter portfolio included the First Trust US IPO Index (FPX), rising 3.27%; iShares MSCI Ireland Capped Investable Market Index (EIRL), climbing 1.75%; and Visa […]
The Red-Hot Sector Beating the S&P 500 by Three to One
Biotechnology is a high-octane sector where fortunes are made and lost quickly.